Latest Intelligence on Pharmaceuticals and Healthcare in Europe

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Type 2 diabetes driving epidemic

Type 2 diabetes poses one of the greatest public health threats of the 21st century. As well as increasing the potential patient population, type 2 diabetes has also raised the profile of the disease. However, a new Datamonitor report estimates that while 55 million people are affected by type 2 diabetes, only 50% of patients are diagnosed, and only 80% of those actually receive treatment.

Published By Datamonitor
21 Feb 2008
CommentWire
CommentWire

Type 1 diabetes: islet cell therapy is not a cure yet

Islet cell transplants use islet cells harvested from cadavers, and promise a cure for type 1 diabetes. However their potential is limited by the early stage of development and a need for further research to make sure that patients can continue to live an insulin-free life without suffering the side effects of the immunosuppressive drugs that they will be required to take.

Published By Datamonitor
10 Mar 2005
CommentWire
CommentWire

Tuberculosis: governments need to take action

If a TB epidemic were to occur, the impact could far outweigh the risks more publicized infections such as HIV and meningitis. The current treatments could leave many patients uncured, and there is little in the pipeline to replace them. Governments should consider subsidizing research into more effective drugs, or risk facing the consequences.

Published By Datamonitor
26 Mar 2002
ResearchWire
ResearchWire

Traumatic brain injuries: numbers will rise in US, fall in Germany and Italy

Published By Datamonitor
13 Nov 2001
ResearchWire
ResearchWire

Trauma devices: Hungarian market to grow 52%

Published By Datamonitor
28 Mar 2002
ResearchWire
ResearchWire

Transplantation: Astellas takes the lead

Published By Datamonitor
18 May 2006
ResearchWire
ResearchWire

Transplantation: a growing but tricky market

Published By Datamonitor
21 Aug 2006
ResearchWire
ResearchWire

Transplantation: a growing but problematic market

Published By Datamonitor
27 Oct 2006
Expert View
Expert View

Tough competitive environment in Europe will hinder Dendreon's plans for Provenge

The European prostate cancer treatment space is currently characterized by economic austerity and strict regulation. Nevertheless, Dendreon is preparing to launch Provenge in the region in an attempt to counter the vaccine's disappointing US launch in April 2010. However, given the considerable hurdles for new cancer drugs in Europe, the company will be forced to rely on revenue growth elsewhere.

Published By Datamonitor
07 Feb 2012
CommentWire
CommentWire

Top pharmaceutical and biotech companies face slowdown in sales growth over 2008-14

A Datamonitor report has identified that the leading pharmaceutical and biotech companies face a major slowdown in sales growth out to 2014, primarily a result of the imminent patent expiries facing many blockbusters and the subsequent threat from generics. Prescription sales are expected to rise at a compound annual growth rate of just 1.2% over 2008-14, compared to a historical rate of 10.5%.

Published By Datamonitor
01 Mar 2010

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.